The Medicines Company (NASDAQ: -MDCO) announced that the results of ESCAPE -2, a pivotal Phase 3 efficacy trial of its investigational agent Cleviprex™ (clevidipine butyrate) injectable emulsion, were published in the July issue of the journal Anesthesia and Analgesia. The clinical trial demonstrated that Cleviprex is effective and safe in the rapid treatment of acute hypertension after cardiac surgery. ESCAPE-2, a randomized, double-blind, placebo-controlled trial, examined the efficacy and safety of Cleviprex in treating patients with acutely elevated blood pressure after cardiac surgery. A total of 110 patients with a systolic blood pressure (SBP) greater than 140 mm Hg following cardiac surgery were randomized to a 30 to 60 minute infusion of Cleviprex or placebo. The primary end point was the incidence of treatment...
[read full story]
Your Web Site
